Conductus ships first supercon probe
Conductus of Sunnyvale, CA, has made the first commercial shipmentof its SuperProtonnmr high-temperature superconducting probefor NMR spectroscopy. The probe, which is being distributed byVarian Associates as part of its Unity Inova spectrometer
Conductus of Sunnyvale, CA, has made the first commercial shipmentof its SuperProtonnmr high-temperature superconducting probefor NMR spectroscopy. The probe, which is being distributed byVarian Associates as part of its Unity Inova spectrometer system,was shipped to the National High Magnetic Field Lab at FloridaState University in Tallahassee.
SuperProtonnmr uses coils made of the high-temperaturesuperconductor yttrium barium copper oxide (SCAN 4/24/96). Conductusclaims that the probe is four times as sensitive as conventionalNMR probes, allowing the analysis of much smaller samples.
In other Conductus news, the company this month announced adistribution agreement with Nalorac, a Martinez, CA, manufacturerand distributor of NMR probes. The deal will expand the distributioncoverage available for Conductus' high-temperature superconductingprobes, as Nalorac supplies conventional NMR probes to all majorNMR manufacturers.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
